Özgün CUVAŞ, Fatih BAKIR, Başak PEHLİVAN, Hülya BAŞAR, Beyazıt DİKMEN, Hüseyin ÜSTÜN

Comparison of the effects of repeated dose treatments of lornoxicam and meloxicam on renal functions in rats

We aimed to investigate the renal effects of meloxicam, a preferential cyclooxygenase-2 inhibitor nonsteroidal antiiflammatory drug, and lornoxicam, a nonspecific cyclooxygenase inhibitor, in rats. We wanted to test the hypothesis that preferential cyclooxygenase-2 inhibitors have a higher renal safety profile when compared with the nonspecific cyclooxygenase inhibitors. Materials and methods: Thirty healthy male Sprague-Dawley rats were included in the study. During the study period, 0.9% NaCl, 5.8 mg kg-1 meloxicam, or 1.3 mg kg-1 lornoxicam were given in 1 mL volumes once daily by the peritoneal route. On day 14, rats were placed in metabolic cages and their urine was collected for 24 h. After anesthesia was administered, blood samples were taken, followed by nephrectomy. Results: Serum sodium, potassium, creatinine, BUN, urine NAG (N-acetyl-beta-D-glucosaminidase), protein, and density values increased, while urine volume, sodium, potassium, creatinine values, and creatinine clearance decreased significantly in both groups when compared with the control. In the meloxicam group, serum potassium, BUN, and urine density values were greater than those of the lornoxicam group. In the lornoxicam group, serum sodium and urine NAG values were greater than those of the meloxicam group. Conclusion: We want to emphasize that meloxicam must be used with caution, similarly to nonspecific cyclooxygenase inhibitors.

Anahtar Kelimeler:

Key words: Nonsteroidal antiiflammatory drugs, renal problems

Comparison of the effects of repeated dose treatments of lornoxicam and meloxicam on renal functions in rats

Keywords:

Key words: Nonsteroidal antiiflammatory drugs, renal problems,

PDF

___

Patoia I, Santucci I, Furno P, Dionisi MS, Dell’orso S, Romagnoli M et al. A four-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptoms evaluation in healthy volunteers. Br J Rheumatol 1996; 35: 61-7.
Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized double-blind, placebo-controlled trial. Arthritis Rheum 2000; 43: 370-7.
Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83.
Emery P, Zeidel H, Kvien TK, Guslandi M, Naudin R, Stead H et al. Celecoxib versus diclofenac in long term management of rheumatoid arthritis: a randomized double blind comparison. Lancet 1999; 354: 2106-11.
Eras J, Perazella MA. NSAIDs and the kidney revisited: are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci 2001; 321: 181-190.
Engelhardt G. Pharmacology of meloxicam, a new non-steroid anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996; 35 (Suppl. 1): 4-12.
Engelhardt G, Trummlitz G. Biological activity of the main metabolites of meloxicam. Drugs Exptl Clin Res 1990; 16: 53-6.
Balfour JA, Fitton A, Barradell LB. Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639-57.
Warrington SJ, Lewis Y, Dawnay A, Johnston A, Kovacs IB, Lamb E et al. Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation. Postgrad Med J 1990; 66 (Suppl. 4): 35-40.
Pruss TP, Stroibnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F et al. Overview of the pharmalogical properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 1990; 66 (Suppl. 4): 18-21.
Bevis PJR, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 1996; 35 (Suppl. 1): 56-60.
Müller FO, Middle MV, Schall R, Terblanche J, Hundt HKL, Groenewoud G et al. An evaluation of the interaction of meloxicam with furosemide in patients with compensated chronic cardiac failure. Br J Clin Pharmacol 1997; 44: 393-8.
Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Begaud B et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-45.
Dequeker J, Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX-2) inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large- scale evaluation of COX- inhibiting therapies (select) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51.